Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides drug substance as fast as 13 months at competitive prices. The novel program is called 'Lean-to-Clinic' and leverages Boehringer Ingelheim's established platforms and processes for the production of monoclonal antibodies using the proprietary BI-HEX® high expression system.
43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will today be awarded Novo Scholarships, the largest of their kind in Denmark. "We must learn how to nurture the wealth of research talent to be found in Denmark. The Novo Scholarships are a good example of this and can inspire more young people to become interested in the natural sciences," says Morten Østergaard, Danish Minister for Research, Innovation and Higher Education.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® (SOM230, pasireotide) for the treatment of Cushing's disease. There are currently no approved medicines in the European Union (EU) targeting Cushing's disease, a debilitating endocrine disorder caused by excess cortisol in the body due to the presence of a non-cancerous pituitary tumor[1],[2].|
Lower profit margins suggest a need for new business models. Read more on the McKinsey Quarterly > |
Topics:
|
|
A daunting array of financial and operational barriers is holding back growth. What can be done? Read more on the McKinsey Quarterly > |
Topics:
|
|
A member of the executive board describes how the Dutch insurance group first transformed its health division and then started to roll out the changes across the entire company. Read more on the McKinsey Quarterly > |
Topics:
|